세계의 이중 특이성 항체 시장 규모 조사 및 예측 : 적응증별 및 지역별 분석(2023-2030년)

Global Bispecific Antibodies Market is valued at approximately USD 5.73 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 44.0% over the forecast period 2023-2030. Bispecific antibodies are a class of therapeutic proteins created to attach to two distinct target molecules simultaneously. These antibodies have two separate antigen-binding sites that recognize a different antigen or receptor because of genetic engineering. Bispecific antibodies assemble these molecules, control their interactions, or transport medicinal substances to body parts by attaching two distinct targets. Bispecific antibodies provide several benefits compared to conventional monoclonal antibodies, which normally bind to a single target. They are used to target numerous disease-related pathways concurrently or to divert immune cells away from healthy tissue and toward tumor cells. The growing demand for targeted and personalized therapies, significant advancements in antibody engineering technologies, along with increasing collaborations and partnerships between local and international stakeholders are the key factors that are propelling the market demand during the estimated period.

In addition, the surge in the incidences of cancer cases is fueling the demand for a range of treatment alternatives including biospecific antibodies particularly those designed as immune checkpoint inhibitors or T cell engagers, which, in turn, accelerating the market growth across the world. According to The Global Cancer Observatory (GCO), in 2020, about 19.3 million new cases of cancer were reported worldwide and this number is expected to increase to 30.2 million in the year 2040. Biospecific antibodies redirect immune cells to attack tumor cells, leading to tumor regression and improved patient outcomes. Moreover, the increasing investment in biologics research and development, as well as the robust growth of the biopharmaceutical pipeline present various lucrative opportunities over the forecast years. However, the complex development and manufacturing and regulatory challenges are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Bispecific Antibodies Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing approval for several bispecific antibodies by regulatory bodies, growing investment in R&D activities, along with the presence of several leading market players. For instance, in October 2022, the first bispecific B-cell maturation antigen, teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), received FDA approval. In addition, companies are increasingly participating in partnerships and collaborations to use complementary scientific expertise and technology to create bispecific antibodies. These partnerships promoted research and development initiatives, which has further accelerated market expansion. Europe is expected to grow at a substantial CAGR over the forecast years. The surging demand for bispecific antibodies, rising focus on technological advancements, as well as increasing collaborations and partnerships between local and international stakeholders are significantly propelling the market demand across the region.

Major market players included in this report are:

• Amgen, Inc.
• Bayer AG
• Dow Pharmaceutical Solutions
• ImmunGene, Inc.
• Immunocore Limited
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• F. Hoffmann-La Roche AG
• Akeso, Inc.

Recent Developments in the Market:

• In January 2023, Genentech, Inc., an American biotechnology corporation announced that the company has received FDA approval for the company's bispecific antibody that is specially designed for lymphoma. This approval enables the company to market their bispecific antibody across the region.
• In May 2023, Genmab A/S unveiled that the U.S. Food and Drug Administration (FDA) has approved EPKINL (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma, following two or more lines of systemic therapy.

Global Bispecific Antibodies Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Indication, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Indication:

• Cancer
• Inflammatory & Autoimmune Disorders
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Bispecific Antibodies Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Bispecific Antibodies Market, by Indication, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Bispecific Antibodies Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Bispecific Antibodies Market Dynamics

• 3.1. Bispecific Antibodies Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing demand for targeted and personalized therapies
    • 3.1.1.2. Surge in the incidences of cancer cases
  • 3.1.2. Market Challenges
    • 3.1.2.1. Complex development and manufacturing
    • 3.1.2.2. Regulatory challenges
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Increasing investment in biologics research and development
    • 3.1.3.2. Robust growth of the biopharmaceutical pipeline

Chapter 4. Global Bispecific Antibodies Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Bispecific Antibodies Market, by Indication

• 5.1. Market Snapshot
• 5.2. Global Bispecific Antibodies Market by Indication, Performance - Potential Analysis
• 5.3. Global Bispecific Antibodies Market Estimates & Forecasts by Indication 2020-2030 (USD Billion)
• 5.4. Bispecific Antibodies Market, Sub Segment Analysis
  • 5.4.1. Cancer
  • 5.4.2. Inflammatory & Autoimmune Disorders
  • 5.4.3. Others

Chapter 6. Global Bispecific Antibodies Market, Regional Analysis

• 6.1. Top Leading Countries
• 6.2. Top Emerging Countries
• 6.3. Bispecific Antibodies Market, Regional Market Snapshot
• 6.4. North America Bispecific Antibodies Market
  • 6.4.1. U.S. Bispecific Antibodies Market
    • 6.4.1.1. Indication breakdown estimates & forecasts, 2020-2030
  • 6.4.2. Canada Bispecific Antibodies Market
• 6.5. Europe Bispecific Antibodies Market Snapshot
  • 6.5.1. U.K. Bispecific Antibodies Market
  • 6.5.2. Germany Bispecific Antibodies Market
  • 6.5.3. France Bispecific Antibodies Market
  • 6.5.4. Spain Bispecific Antibodies Market
  • 6.5.5. Italy Bispecific Antibodies Market
  • 6.5.6. Rest of Europe Bispecific Antibodies Market
• 6.6. Asia-Pacific Bispecific Antibodies Market Snapshot
  • 6.6.1. China Bispecific Antibodies Market
  • 6.6.2. India Bispecific Antibodies Market
  • 6.6.3. Japan Bispecific Antibodies Market
  • 6.6.4. Australia Bispecific Antibodies Market
  • 6.6.5. South Korea Bispecific Antibodies Market
  • 6.6.6. Rest of Asia Pacific Bispecific Antibodies Market
• 6.7. Latin America Bispecific Antibodies Market Snapshot
  • 6.7.1. Brazil Bispecific Antibodies Market
  • 6.7.2. Mexico Bispecific Antibodies Market
• 6.8. Middle East & Africa Bispecific Antibodies Market
  • 6.8.1. Saudi Arabia Bispecific Antibodies Market
  • 6.8.2. South Africa Bispecific Antibodies Market
  • 6.8.3. Rest of Middle East & Africa Bispecific Antibodies Market

Chapter 7. Competitive Intelligence

• 7.1. Key Company SWOT Analysis
  • 7.1.1. Company 1
  • 7.1.2. Company 2
  • 7.1.3. Company 3
• 7.2. Top Market Strategies
• 7.3. Company Profiles
  • 7.3.1. Amgen, Inc.
    • 7.3.1.1. Key Information
    • 7.3.1.2. Overview
    • 7.3.1.3. Financial (Subject to Data Availability)
    • 7.3.1.4. Product Summary
    • 7.3.1.5. Recent Developments
  • 7.3.2. Bayer AG
  • 7.3.3. Dow Pharmaceutical Solutions
  • 7.3.4. ImmunGene, Inc.
  • 7.3.5. Immunocore Limited
  • 7.3.6. Merck & Co., Inc.
  • 7.3.7. Novartis AG
  • 7.3.8. Pfizer, Inc.
  • 7.3.9. F. Hoffmann-La Roche AG
  • 7.3.10. Akeso, Inc.

Chapter 8. Research Process

• 8.1. Research Process
  • 8.1.1. Data Mining
  • 8.1.2. Analysis
  • 8.1.3. Market Estimation
  • 8.1.4. Validation
  • 8.1.5. Publishing
• 8.2. Research Attributes
• 8.3. Research Assumption